Tetranectin targeting by epigallocatechin gallate suppresses colon cancer cell proliferation

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Tetranectin is a serum protein implicated in the development of various carcinomas, including colon cancer.
• Tetranectin facilitates the proteolytic activation of plasminogen, contributing to cancer progression.

Purpose of the Study:

• To investigate the potential of natural products to inhibit tetranectin's function.
• To explore epigallocatechin gallate as a therapeutic agent targeting tetranectin in colon cancer.

Main Methods:

• Structure-based in silico screening of natural products for tetranectin binding.
• Confirmation of epigallocatechin gallate-tetranectin binding using intrinsic fluorescence quenching and isothermal titration calorimetry.
• Assessment of epigallocatechin gallate's effect on tetranectin-mediated plasminogen activation and CT-26 colon cancer cell proliferation.

Main Results:

• Epigallocatechin gallate was identified as a natural product that binds to tetranectin.
• Binding was experimentally confirmed, and epigallocatechin gallate demonstrated inhibition of tetranectin's enhancement of plasminogen activation.
• Tetranectin was shown to promote CT-26 colon cancer cell proliferation; epigallocatechin gallate suppressed this proliferation by inhibiting tetranectin.

Conclusions:

• Epigallocatechin gallate exhibits anticancer effects against colon cancer cells by targeting tetranectin.
• Inhibition of tetranectin by epigallocatechin gallate is a key mechanism underlying its cytotoxic activity.
• Tetranectin represents a potential therapeutic target for colon cancer treatment, with epigallocatechin gallate as a promising modulator.